ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Two collaborations pursue the microbiome

by Lisa M. Jarvis
August 21, 2016 | APPEARED IN VOLUME 94, ISSUE 33

Vedanta Biosciences has teamed with NYU Langone Medical Center to develop microbiome-derived immunotherapies for cancer patients receiving checkpoint inhibitors. The partners hope to understand how the gut microbiome affects the efficacy of checkpoint inhibitors and potentially develop drugs to modulate that interaction. In a separate microbiome-related pact, Johnson & Johnson will explore skin disease treatments with Xycrobe Therapeutics. Xycrobe has developed a library of “good” skin bacteria engineered to secrete therapeutics.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment